Hepatocellular Carcinoma Non-resectable
Conditions
Brief summary
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus.
Detailed description
After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days. Patients will be performed enhanced CT/MRI every 2 months, to access the efficiency according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, undergoing enhanced CT/MRI. The overall survival (OS) was calculated as the time from enrollment until death or the last follow-up. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 to access the safety.
Interventions
COMBINATION_PRODUCTradiotherapy combined with sintilimab and bevacizumab biosimilar
After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
Sponsors
Yongchang Zhang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Hepatocellular carcinoma confirmed by histology/cytology, or patients with cirrhosis and meet the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria for HCC 2. Child-pugh grade A or B (≤7 points) 3. A score of 0-1 according to the Eastern Cooperative Oncology Group Physical Status Score (ECOG PS score); 4. Barcelona stage C; Inamicable for radical surgical resection or refusal of surgery without extra-hepatic metastases; Portal vein tumor thrombus (PVTT) was diagnosed by enhanced CT or enhanced MRI (type VP1 to VP3). 5. Had not received systemic therapy or radiotherapy before; Or disease progression after surgical resection or local treatment (without radiotherapy); 6. At least one measurable or evaluable lesion according to the response evaluation criteria for solid tumors, version 1.1 (RECIST V1.1); Or measurable lesions that had clearly progressed after local treatment (based on RECIST V1.1 criteria). 7. Patients with liver lesions and/or portal vein tumor thrombus lesions were treated with radiotherapy
Exclusion criteria
1. Previous histological/cytological diagnosis included fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, and other components. 2. The area to be treated had been previously treated with radiotherapy 3. Patients with extrahepatic metastases 4. Patients with tumor thrombus invasion into the superior mesenteric vein 5. Patients with inferior vena cava tumor thrombus. 6. Central nervous system metastases were present. 7. A history of hepatic encephalopathy, or a history of liver transplantation. 8. There are clinical symptoms of pleural effusion, ascites, or pericardial effusion that require drainage. 9. Patients with acute or chronic active hepatitis B or C with hepatitis B virus (HBV) DNA\>2000IU/ml or 10\^4 Copies/ml; Hepatitis C virus (HCV)RNA\> 10\^3 Copies/ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody were both positive. 10. History of allergy to active ingredients and/or excipients of anti-PD-1 mab and anti-VEFG mab. 11. Other malignancies, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix, were present within 5 years. 12. Bleeding events from esophageal or gastric fundus varices due to portal hypertension had occurred within the previous 6 months. Severe (G3) varicose veins were known to have been present on endoscopy within 3 months before the first dose. There was evidence of portal hypertension (including splenomegaly on imaging) and a high risk of bleeding as assessed by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response rate | up to 2 years from enrollment | assessed according to the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, undergoing enhanced CT/MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response rate, assessed according to the modified Response Evaluation Criteria | up to 2 years from enrollment | assessed according to the modified Response Evaluation Criteria in Solid Tumors Version 1.1, undergoing enhanced CT/MRI |
| overall survival | up to 2 years from enrollment | the time from enrollment until death or the last follow-up |
| number of participants with treatment-related adverse events | up to 2 years from enrollment | number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
China
Contacts
Primary ContactJia Luo, Professor
Outcome results
None listed